YS Biopharma receives Nasdaq noncompliance notice

YS Biopharma has received written notification from the staff of the Listing Qualifications Department of Nasdaq , indicating that because the closing bid price of the company’s ordinary shares for the last 31 consecutive business days was below US$1.00 per share, the Company no longer meets Nasdaq minimum bid price requirements. The deficiency letter does not result in the immediate delisting of the company’s securities. The company has a compliance period of 180 calendar days, or until April 22, 2024, to regain compliance with Nasdaq’s minimum bid price requirement. If at any time during the compliance period, the closing bid price per share is at least $1.00 for a minimum of 10 consecutive business days, the matter will be closed. In the event that the company does not regain compliance by April 22, 2024, it may be eligible for an additional 180 calendar days compliance period. The company is considering its options in order to regain compliance.